CST, 83687S, Thalidomide

Chemical Modulators for studying in the research area. Product Usage Information Thalidomide is supplied as a lyophilized powder. For a 15 mM stock, reconstitute 5 mg of powder in 1.29 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect. Caution: Teratogenic. May cause harm to the unborn child. Avoid all contact with this product during pregnancy. Storage Store lyophilized at room temperature, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles . Background Thalidomide was briefly used as an antiemetic and sedative to treat "morning sickness," anxiety, and insomnia before being removed from the market due to its association with neonatal mortality and severe birth defects. It reentered the clinical marketplace decades later as an antiangiogenic and anti-inflammatory agent effective against several forms of cancer, leprosy, and some inflammatory disorders (1,2). Thalidomide and its analogs, Lenalidomide and Pomalidomide, are immunomodulatory drugs that bind the CRL4 E3 ubiquitin ligase substrate receptor Cereblon (CRBN) to promote the ubiquitination and targeted degradation of several transcription factors. These compounds target several proteins, including C H zinc finger transcription factors Ikaros, Aiolos, and ZFP91, as well as casein kinase 1α, to control a broad transcriptional network (3,4). Thalidomide can also downregulate the zinc finger transcription factor SALL4, which is implicated in some human malformation syndromes, including Duane-radial ray syndrome (Okihiro syndrome) and Acro-renal-ocular syndrome (5). Alternate Names N-(2,6-dioxo-3-piperidinyl)phthalimide